Photocure Validates BLC Cost-Effectiveness with Novel Health Economic Model
Event summary
- Photocure published a novel health economic methodology in The Journal of Medical Economics comparing BLC and NBI imaging technologies for bladder cancer.
- The study demonstrated BLC is cost-effective versus NBI with an ICER of DKK 70,707 per QALY gained, well below typical cost-effectiveness thresholds.
- The new model addresses data gaps by transforming key data points from clinical studies for responsible and transparent comparisons.
- Network meta-analysis results aligned with BLC reducing recurrence more effectively than NBI, consistent with broader literature.
The big picture
Photocure's publication addresses a critical gap in comparative health economic analysis for bladder cancer diagnostics. The methodology provides a framework for evaluating technologies with disparate evidence bases, which could set a precedent for similar assessments in other medical fields. This strategic move reinforces BLC's value proposition amid rising healthcare cost pressures and the need for evidence-based decision-making.
What we're watching
- Regulatory Adoption
- Whether health authorities beyond Denmark will adopt this novel methodology for cost-effectiveness assessments.
- Market Differentiation
- How Photocure leverages this data to strengthen BLC's position against NBI in competitive markets.
- Clinical Validation
- The pace at which additional long-term data emerges to further substantiate BLC's cost and clinical benefits.
Related topics